Global and Multi-National Prevalence of Fungal Diseases-Estimate Precision
Open accessThe DOI matches its Crossref record; 183 of the 192 references it cites were found in a registry or an index; 48 of the 182 sources its claims cite were checked for support.
Abstract
Fungal diseases kill more than 1.5 million and affect over a billion people. However, they are still a neglected topic by public health authorities even though most deaths from fungal diseases are avoidable. Serious fungal infections occur as a consequence of other health problems including asthma, AIDS, cancer, organ transplantation and corticosteroid therapies. Early accurate diagnosis allows prompt antifungal therapy; however this is often delayed or unavailable leading to death, serious chronic illness or blindness. Recent global estimates have found 3,000,000 cases of chronic pulmonary aspergillosis, ~223,100 cases of cryptococcal meningitis complicating HIV/AIDS, ~700,000 cases of invasive candidiasis, ~500,000 cases of Pneumocystis jirovecii pneumonia, ~250,000 cases of invasive aspergillosis, ~100,000 cases of disseminated histoplasmosis, over 10,000,000 cases of fungal asthma and ~1,000,000 cases of fungal keratitis occur annually. Since 2013, the Leading International Fungal Education (LIFE) portal has facilitated the estimation of the burden of serious fungal infections country by country for over 5.7 billion people (>80% of the world’s population). These studies have shown differences in the global burden between countries, within regions of the same country and between at risk populations. Here we interrogate the accuracy of these fungal infection burden estimates in the 43 published papers within the LIFE initiative.
Overview
CoChat Summary
TL;DR
This review interrogates the accuracy of global and multi-national estimates of serious fungal disease burden generated through the Leading International Fungal Education (LIFE) initiative. It summarizes estimates from 43 published country reports and highlights wide variation, data gaps, and likely underestimation of fungal disease burden.
Key findings
- Recent global estimates include 3,000,000 cases of chronic pulmonary aspergillosis, ~223,100 cases of cryptococcal meningitis complicating HIV/AIDS, ~700,000 cases of invasive candidiasis, ~500,000 cases of *Pneumocystis jirovecii* pneumonia, ~250,000 cases of invasive aspergillosis, ~100,000 cases of disseminated histoplasmosis, over 10,000,000 cases of fungal asthma, and ~1,000,000 cases of fungal keratitis annually.
- Across LIFE country papers, candidaemia burden was 159,253 cases in 39 countries, invasive aspergillosis was 81,927 cases in 40 countries, and *Pneumocystis jirovecii* pneumonia was 133,487 cases in 40 papers; the highest candidaemia prevalence was reported in Pakistan (38,795 cases, 21 per 100,000).
- Chronic pulmonary aspergillosis estimates were highest in India (209,147) and Nigeria (120,753), with an overall incidence of 22 cases per 100,000 (14.2–30.59 95% CI); ABPA was estimated at 3,550,157 cases and SAFS at 4,125,428 cases across 43 countries.
- Tinea capitis was estimated at 21,073,423 cases in just 16 countries, with Nigeria alone accounting for 15,581,400 cases; global recurrent vulvovaginal candidiasis prevalence was estimated at about 134,000,000 cases.
Methods
- Narrative review of 43 published papers within the LIFE initiative, covering >2000 million people (29% of the world population), with the LIFE portal having facilitated estimates for over 5.7 billion people (>80% of the world’s population).
- The paper describes how country-level burden estimates were derived for specific fungal diseases, using published epidemiological data, modelling assumptions, and at-risk population denominators.
- Main analysis is descriptive and comparative: it aggregates country estimates, examines differences by region, country, and at-risk group, and discusses strengths and weaknesses of the estimation methods.
Limitations
- The paper states that a precise estimate of global prevalence and incidence for each fungal infection remains unknown, and data are scanty in most countries, especially in the developing world.
- It states that knowledge is impaired by lack of regular national surveillance, no obligatory reporting of fungal diseases, poor clinician suspicion outside specialised units, poor diagnostic test performance, and few well-designed published studies; estimates are not intended as a substitute for high-quality epidemiological study or comprehensive surveillance.
- It also states that comparisons across countries are difficult because recent local epidemiological data were available for only some countries, data quality varies, not all institutions report infections, and many low- and low-middle-income countries lack blood culture systems; the text makes evident that country estimates rely on heterogeneous assumptions and uniform rates in places, such as 5 per 100,000 for candidaemia when local data were unavailable and 6% for recurrent vulvovaginal candidiasis.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Figures





Verification
Claims the paper makes
33 Valid · 8 Not valid · 70 Not checked · 75 Own results and interpretations
Some cited sources support this claim and some don’t — read each source’s verdict below.
In the paper
“In particular, resistance to fluconazole is common [30,43,44]”
§ Global and Multi-National Prevalence of Fungal Diseases—Estimate Precision > 2. Estimate precision > 2.1. Candidaemia
What the sources say
- Not checked — no full text of the sourcecites [30] Arendrup M.C. Candida and Candidaemia: Susceptibility and Epidemiology Dan. Med. J. 2013 60 1 32 24192246
- Disputedcites [43] Hii I.M. Chang H.L. Lin L.C. Lee Y.L. Liu Y.M. Liu C.E. Chen C.H. Cheng Y.R. Chang C.Y. Changing epidemiology of candidemia in a medical center in middle Taiwan J. Microbiol. Immunol. Infect. 2015 48 306 315 10.1016/j.jmii.2013.08.017 24113067 sourceExperimental — accuracy not yet measured
The Discussion reports an overall fluconazole resistance rate of 4.95% among the clinical Candida isolates, contrary to the unqualified claim that resistance is common. The Antifungal susceptibility section distinguishes resistance from reduced susceptibility: only 4.4% of C. glabrata isolates were resistant, although 66.7% were dose-dependent susceptible. (LLM, conf=0.88)
Checked by a reasoning model — may be wrong.
- Supportedcites [44] Al Thaqafi A.H.O. Farahat F.M. Al Harbi M.I. Al Amri A.F.W. Perfect J.R. Predictors and outcomes of Candida bloodstream infection: Eight-year surveillance, western Saudi Arabia Int. J. Infect. Dis. 2014 21 5 9 10.1016/j.ijid.2013.12.012 24468816 source
The Discussion describes a high level of fluconazole resistance as alarming. The Results report low in vitro susceptibility among Candida bloodstream isolates in the hospital studied, supporting the claim in that setting. (LLM, conf=0.90)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
Every source the paper cites for this claim was checked and supports it.
In the paper
“Modelling with existing outcome data shows that mortality associated with these priority fungal diseases concurrently with the Joint United Nations Program on HIV/AIDS (UNAIDS) 90-90-90 campaign could save over 1.6 million lives of persons living with HIV globally over the next five years [2].”
§ Global and Multi-National Prevalence of Fungal Diseases—Estimate Precision > 1. Introduction
What the sources say
- Supportedcites [2] Denning D.W. Minimizing fungal disease deaths will allow the UNAIDS target of reducing annual AIDS deaths below 500,000 by 2020 to be realized Philos. Trans. R. Soc. B 2016 371 10.1098/rstb.2015.0468 28080991 PMC5095544 source
Split into 2 atoms — 2 confirmed, 0 partially supported, 0 disputed, 0 misattributed, 0 unverifiable. Expand the claim to see per-atom verdicts.
hedgedstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“The burden of infectious (all-cause, including fungal) keratitis in Mexico was estimated based on the prevalence of reported in China (0.148%) [150].”
§ Global and Multi-National Prevalence of Fungal Diseases—Estimate Precision > 2. Estimate precision > 2.6. Fungal Keratitis
What the sources say
- Supportedcites [150] Cao J. Yang Y. Yang W. Wu R. Xiao X. Yuan J. Xing Y. Tan X. Prevalence of infectious keratitis in Central China BMC Ophthalmol. 2014 14 1 6 10.1186/1471-2415-14-43 24690368 PMC3976152 source
The Abstract Results report an infectious keratitis prevalence of 0.148% in Central China and separately include fungal keratitis among its causes. The Mexico estimate is the citing authors’ use of that figure, not a result attributed to this source. (LLM, conf=0.92)
hedgedstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Rests on an assumption not shown here.
- Supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Since 2013, the Leading International Fungal Education (LIFE) portal has facilitated the estimation of the burden of serious fungal infections country by country for over 5.7 billion people (>80% of the world’s population).”
§ Global and Multi-National Prevalence of Fungal Diseases—Estimate Precision > Abstract
What the sources say
- Partly supportedcites [14] Denning D.W. Calling upon all public health mycologists Eur. J. Clin. Microbiol. Infect. Dis. 2017 36 923 924 10.1007/s10096-017-2909-8 28150046 sourceExperimental — accuracy not yet measured
The paper describes systematic country-by-country estimates of serious fungal infections and links to the LIFE site for completed estimates (p. 1). It does not state that the portal facilitated this work since 2013 or that the estimates covered over 5.7 billion people (>80% of the world’s population); its stated figure of 883 million people refers only to the current 14-country series (p. 1). (LLM, conf=0.84)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“HIV/AIDS pandemic, tuberculosis, chronic obstructive pulmonary disease (COPD), asthma and the increasing incidence of cancers are the major drivers of fungal infections in both developed and developing countries globally [1,2,3,4,5,6].”
§ Global and Multi-National Prevalence of Fungal Diseases—Estimate Precision > 1. Introduction
What the sources say
- Not checked — no full text of the sourcecites [1] Brown G.D. Denning D.W. Gow N.A.R. Levitz S.M. Netea M.G. White T.C. Hidden Killers: Human Fungal Infections Sci. Transl. Med. 2012 4 1 9 10.1126/scitranslmed.3004404 23253612 source
- Partly supportedcites [2] Denning D.W. Minimizing fungal disease deaths will allow the UNAIDS target of reducing annual AIDS deaths below 500,000 by 2020 to be realized Philos. Trans. R. Soc. B 2016 371 10.1098/rstb.2015.0468 28080991 PMC5095544 sourceExperimental — accuracy not yet measured
The Introduction identifies major fungal diseases complicating HIV, and the section on chronic pulmonary aspergillosis complicating tuberculosis in HIV-positive patients names TB and COPD as underlying pulmonary disorders (page unavailable). The paper does not identify asthma or increasing cancer incidence as drivers, nor does it establish that the listed conditions are the major drivers of fungal infections globally across developed and developing countries. (LLM, conf=0.88)
- Not checked — no full text of the sourcecites [3] Armstrong-James D. Meintjes G. Brown G.D. A neglected epidemic: Fungal infections in HIV/AIDS Trends Microbiol. 2014 22 120 127 10.1016/j.tim.2014.01.001 24530175 source
- Not checked — no full text of the sourcecites [4] Guinea J. Torres-Narbona M. Gijón P. Muñoz P. Pozo F. Peláez T. de Miguel J. Bouza E. Pulmonary aspergillosis in patients with chronic obstructive pulmonary disease: Incidence, risk factors, and outcome Clin. Microbiol. Infect. 2010 16 870 877 10.1111/j.1469-0691.2009.03015.x 19906275 source
- Not checked — no full text of the sourcecites [5] Marr K.A. Carter R.A. Boeckh M. Martin P. Corey L. Invasive aspergillosis in allogeneic stem cell transplant recipients: Changes in epidemiology and risk factors Blood 2002 100 4358 4366 10.1182/blood-2002-05-1496 12393425 source
- Not checked — no full text of the sourcecites [6] Limper A.H. Adenis A. Le T. Harrison T.S. Fungal infections in HIV/AIDS Lancet Infect. Dis. 2017 10.1016/S1473-3099(17)30303-1 28774701 source
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
52 more claims · 6 with their cited sources checked
Create a free account to see all 186 claims and to verify the 39 references still open.
- Probably not a substantial claim. 80
- It may state two separate claims as one. 82
- The quote only partly states this claim. 1
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Although the target organ of A. fumigatus is the lungs, Aspergillus is known to be angiotropic and has an affinity for host vasculature. As growing hyphae penetrate pulmonary tissues, they can invade the endothelial lining of nearby blood vessels and break off into circulation, causing sepsis and dissemination accompanied by thrombosis, hemorrhagic infarction and invasion of distant organs [8, 164”
From Mechanisms of fungal dissemination (2021) · cites this paper as [8]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Fungal pathogens are responsible for at least 13 million infections and 1.5 million deaths globally per year, primarily in those with some compromised immune function [1].”
From Prevalence and Healthcare Burden of Fungal Infections in the United States, 2018 (2022) · cites this paper as [1]
Experimental — accuracy not yet measuredIn the citing paper
“In healthy individuals, these conidia are rapidly cleared, but in the case of immunocompromised patients, conidia can germinate and develop filamentous hyphae [1, 166]. This fungal growth can result in invasive aspergillosis: a severe and aggressive fungal disease characterized by tissue damage, necrosis and hypoxia [8, 164, 167].”
From Mechanisms of fungal dissemination (2021) · cites this paper as [8]
In the citing paper
“Candida albicans the primary species responsible for mucosal disease”
From Acquisition of cross-azole tolerance and aneuploidy in Candida albicans strains evolved to posaconazole (2022) · cites this paper as Bongomin et al. 2017
In the citing paper
“Deep-seated candidiasis, arising from direct inoculation or hematogenous dissemination of Candida into normally sterile body sites, is often difficult to diagnose and may affect a population as large as that of candidemia [4,5,6].”
From Treatment of Invasive Candidiasis: A Narrative Review (2018) · cites this paper as [4]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
Each contradiction between two passages listed here was confirmed by an independent check.
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ Global and Multi-National Prevalence of Fungal Diseases—Estimate Precision > 2. Estimate precision > 2.5. Allergic Bronchopulmonary Aspergillosis (ABPA) & Severe Asthma with Fungal Sensitisation (SAFS)
“28,447 [2.5% of 1,136,092] (62 per 100,000) patients with ABPA”
§ Global and Multi-National Prevalence of Fungal Diseases—Estimate Precision > 2. Estimate precision > 2.5. Allergic Bronchopulmonary Aspergillosis (ABPA) & Severe Asthma with Fungal Sensitisation (SAFS)
“37,491 [3.33% of 1,136,092] (37.5 per 100,000) with severe asthma with fungal sensitisation (SAFS)”
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ Global and Multi-National Prevalence of Fungal Diseases—Estimate Precision > 2. Estimate precision > 2.5. Allergic Bronchopulmonary Aspergillosis (ABPA) & Severe Asthma with Fungal Sensitisation (SAFS)
“Average incidence is 154 cases per 100,000 (SD ± 654)”
§ Global and Multi-National Prevalence of Fungal Diseases—Estimate Precision > 2. Estimate precision > 2.5. Allergic Bronchopulmonary Aspergillosis (ABPA) & Severe Asthma with Fungal Sensitisation (SAFS)
“the highest incidence rates reported in United Kingdom (654 per 100,000)”
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ Global and Multi-National Prevalence of Fungal Diseases—Estimate Precision > 2. Estimate precision > 2.1. Candidaemia
“The total burden of candidaemia is 159,253 cases across these 39 countries with available data.”
§ Global and Multi-National Prevalence of Fungal Diseases—Estimate Precision > 2. Estimate precision > 2.1. Candidaemia
“Europe (n = 1 country, 420,549 cases)”
Citations
Cites
Vos, T., Flaxman, A. D., Naghavi, M., Lozano, R., Michaud, C., Ezzati, M., Shibuya, K., Salomon, J. A., Abdalla, S., Aboyans, V., et al. (2012) · The Lancet · doi:10.1016/s0140-6736(12)61729-2 · Cited by 8,291
Wang, H., Naghavi, M., Allen, C., Barber, R. M., Bhutta, Z. A., Carter, A., Casey, D. C., Charlson, F. J., Chen, A. Z., Coates, M. M., et al. (2016) · The Lancet · doi:10.1016/s0140-6736(16)31012-1 · Cited by 6,596
Wisplinghoff, H., Bischoff, T., Tallent, S. M., Seifert, H., Wenzel, R. P., & Edmond, M. B. (2004) · Clinical Infectious Diseases · doi:10.1086/421946 · Cited by 4,496 · cited 1×
“Candidaemia is the most common form of invasive candidiasis associated with an unacceptably high mortality rates in excess of 40% even with the introduction of newer antifungal agents [30,32,33].”
BackgroundHidden Killers: Human Fungal Infections
Brown, G. D., Denning, D. W., Gow, N. A. R., Levitz, S. M., Netea, M. G., & White, T. C. (2012) · Science Translational Medicine · doi:10.1126/scitranslmed.3004404 · Cited by 4,284 · cited 1×
“Pneumocystis jirovecii pneumonia is emerging as a leading cause of infection in HIV/AIDS patients [1].”
BackgroundSelf-citationGlobal burden of disease of HIV-associated cryptococcal meningitis: an updated analysis
Rajasingham, R., Smith, R. M., Park, B. J., Jarvis, J. N., Govender, N. P., Chiller, T. M., Denning, D. W., Loyse, A., & Boulware, D. R. (2017) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(17)30243-8 · Cited by 1,861 · cited 1×
“[8], Fungal Infection Trust [12], Global Action Fund for Fungal Infection (GAFFI) Roadmap [9], and van de Sande [13].”
BackgroundSelf-citationGlobal asthma prevalence in adults: findings from the cross-sectional world health survey
To, T., Stanojevic, S., Moores, G., Gershon, A. S., Bateman, E. D., Cruz, A. A., & Boulet, L.-P. (2012) · BMC Public Health · doi:10.1186/1471-2458-12-204 · Cited by 1,521 · cited 1×
“6% respectively among individuals aged 18 to 45 years [142].”
BackgroundKullberg, B. J., & Arendrup, M. C. (2015) · New England Journal of Medicine · doi:10.1056/nejmra1315399 · Cited by 1,315 · cited 1×
“Candidaemia is the most common form of invasive candidiasis associated with an unacceptably high mortality rates in excess of 40% even with the introduction of newer antifungal agents [30,32,33].”
BackgroundSobel, J. D. (2007) · The Lancet · doi:10.1016/s0140-6736(07)60917-9 · Cited by 1,270
Marr, K. A., Carter, R. A., Boeckh, M., Martin, P., & Corey, L. (2002) · Blood · doi:10.1182/blood-2002-05-1496 · Cited by 957
(2006) · PubMed · Cited by 906
Research works printed but not linked: 6
- Denning D.W. Global fungal Burden Mycoses 2013 56 13
- The Fungal Infection Trust How common are fungal diseases? Proceedings of the Fungal Research Trust 20th Anniversary Meeting London, UK 18 June 2011 updated August 2017, London, UK 2017 Available online: http://www.fungalinfectiontrust.org/wp-content/uploads/2015/12/How-Common-are-Fungal-Diseases-v12.2.pdf (accessed on 12 September 2017)
- Jayasekera P.I. Denning D. Perera P. Fernando A. Kudavidanage S. The burden of serious fungal infections in Sri Lanka Mycoses 2013 56 103
- Beardsley J. Denning D. Chau N. Crump J. Day J. Estimating the burden of fungal diseases in Vietnam Eur. Conf. Clin. Microbiol. Infect. Dis. Published Online First: 2014 Available online: http://eccmid.meetingxpert.net/ECCMID_699/poster_108496/program.aspx/anchor108496 (accessed on 31 August 2017)
- Gugnani H.C. Denning D.W. Rahim R. Sadat A. Belal M. Mahbub M.S. Medina N. Samayoa B. Lau-Bonilla D. Denning D.W. Burden of serious fungal infections in Bangladesh Eur. J. Clin. Microbiol. Infect. Dis. 2017 36 965 969 10.1007/s10096-017-2921-z 28161744 · DOI · Paper page
- Samayoa B. Isern V. Serra L. Rivera B.E. Nikiforov M. Arathoon E. Samayoa C. Vallès X. Prieto L. Álvarez C. Preliminary results of a prospective cohort of HIV+ patients in Guatemala Proceedings of the XVIII International AIDS Conference Vienna, Austria 18–23 July 2010
Cited by
Items 301–400 of 2,932
Chemical Composition and Antifungal Activity of Myrcia multiflora and Eugenia florida Essential Oils
Ferreira, O. O., da Silva, S. H. M., de Oliveira, M. S., & Andrade, E. H. D. A. (2021) · Molecules · doi:10.3390/molecules26237259 · Cited by 49
“In addition, in some cases they can be pathogenic due to the production of mycotoxins [2], which favor the triggering of relatively mild diseases and infections, such as in the skin and mucosa, and can worsen, affecting multiple organs [3], such as nails, lungs and hair [4].”
BackgroundPalmieri, F., Koutsokera, A., Bernasconi, E., Junier, P., von Garnier, C., & Ubags, N. D. J. (2022) · Frontiers in Medicine · doi:10.3389/fmed.2022.832510 · Cited by 66
“CPA, including aspergilloma, is estimated to affect more than 3 million people worldwide (1).”
BackgroundInfluentialDermatopathology and the Diagnosis of Fungal Infections
Howell, S. A. (2023) · British Journal of Biomedical Science · doi:10.3389/bjbs.2023.11314 · Cited by 59
“Many systemic infections occur in immune compromised patients and the prevalence of these infections varies according to patient risk factors, country or region, and availability of surveillance data (1).”
BackgroundOladele, R. O., Bongomin, F., Gago, S., & Denning, D. W. (2017) · Journal of Fungi · doi:10.3390/jof3040067 · Cited by 53
“The pathogenic encapsulated yeasts in the genus Cryptococcus remains one of the most important opportunistic fungal pathogens worldwide [1].”
BackgroundSelf-citationDietl, A., Meir, Z., Shadkchan, Y., Osherov, N., & Haas, H. (2018) · Virulence · doi:10.1080/21505594.2018.1482181 · Cited by 54
“reductive iron assimilation [17] Light regulation/response [4] Ergosterol biosynthesis [6] Amino acid biosynthesis [3] Respiration/TCA cycle [1] ß-Oxidation [4] Purine catabolism [1] Nitrate assimilation/NO detoxification [5] REDOX homeostasis [4] Pyridoxin biosynthesis [1] Pantothenic acid biosynthesis [4] Nicotinic…”
BackgroundMethodCallus Culture for the Production of Therapeutic Compounds
Benjamin, E. D., Ishaku, G. A., Andrew, F. P., & Afolabi, A. S. (2019) · American Journal of Plant Biology · doi:10.11648/j.ajpb.20190404.14 · Cited by 48
Dectin-2-Targeted Antifungal Liposomes Exhibit Enhanced Efficacy
Ambati, S., Ellis, E. C., Lin, J., Lin, X., Lewis, Z., & Meagher, R. B. (2019) · mSphere · doi:10.1128/msphere.00715-19 · Cited by 61
The Burden of Fungal Infections in Ethiopia
Tufa, T. B., & Denning, D. W. (2019) · Journal of Fungi · doi:10.3390/jof5040109 · Cited by 45
“Robust estimates of fungal disease incidence and prevalence are lacking in Ethiopia [2].”
BackgroundResultInfluentialSelf-citationOne Health aspects & priority roadmap for fungal diseases: A mini-review
Banerjee, S., Denning, D. W., & Chakrabarti, A. (2021) · The Indian Journal of Medical Research · doi:10.4103/ijmr.ijmr_768_21 · Cited by 55
Self-citationSerious fungal disease incidence and prevalence in Indonesia
Wahyuningsih, R., Adawıyah, R., Sjam, R., Prihartono, J., Wulandari, E. A. T., Rozaliyani, A., Ronny, R., Imran, D., Tugiran, M., Siagian, F. E., et al. (2021) · Mycoses · doi:10.1111/myc.13304 · Cited by 78
Self-citationInvasive Fungal Diseases in Africa: A Critical Literature Review
Bongomin, F., Ekeng, B. E., Kibone, W., Nsenga, L., Olum, R., Itam-Eyo, A. E., Kuate, M. P. N., Pebolo, P. F., Davies, A. A., Manga, M., et al. (2022) · Journal of Fungi · doi:10.3390/jof8121236 · Cited by 53
“The incidence rises with an increase in immunosuppression [102] because the phagocytic and neutrophilic functions of the immune system that prevent conidia germination are impaired [103].”
BackgroundSelf-citationCandida Species in the Urinary Tract: Is it a Fungal Infection or Not?
Dias, V. C. (2020) · Future Microbiology · doi:10.2217/fmb-2019-0262 · Cited by 57
Our current clinical understanding of Candida biofilms: where are we two decades on?
Ramage, G., Borghi, E., Rodrigues, C. F., Kean, R., Williams, C., & Lopez-Ribot, J. L. (2023) · Apmis · doi:10.1111/apm.13310 · Cited by 50
“Despite the lack of definitive data to demonstrate the burden of disease, some have estimated that over 1 billion people are affected by fungal disease, which in turns kills 1.5 million annually (11).”
InfluentialReview of the novel antifungal drug olorofim (F901318)
Vanbiervliet, Y., Nieuwenhuyse, T. V., Aerts, R., Lagrou, K., Spriet, I., & Maertens, J. A. (2024) · BMC Infectious Diseases · doi:10.1186/s12879-024-10143-3 · Cited by 58
Steenwyk, J. L., Mead, M. E., de Castro, P. A., Valero, C., Damásio, A., Santos, R., LaBella, A. L., Li, Y., Knowles, S. L., Raja, H. A., et al. (2021) · Microbiology Spectrum · doi:10.1128/spectrum.00010-21 · Cited by 43
“tions are estimated to occur annually and have high mortality rates (15).”
BackgroundTargeting Virulence Factors of Candida albicans with Natural Products
Bu, Q., Bao, M.-Y., Yang, Y., Wang, T.-M., & Wang, C. (2022) · Foods · doi:10.3390/foods11192951 · Cited by 54
“affects more than 400,000 people each year, with a 50% fatality rate among these individuals [1,2].”
BackgroundMolecular targets for antifungals in amino acid and protein biosynthetic pathways
Kuplińska, A., & Rząd, K. (2021) · Amino Acids · doi:10.1007/s00726-021-03007-6 · Cited by 53
Beyond resistance: antifungal heteroresistance and antifungal tolerance in fungal pathogens
Yang, F., & Berman, J. (2024) · Current Opinion in Microbiology · doi:10.1016/j.mib.2024.102439 · Cited by 42
Fungal cell wall components modulate our immune system
Briard, B., Fontaine, T., Kanneganti, T.-D., Gow, N. A. R., & Papon, N. (2021) · The Cell Surface · doi:10.1016/j.tcsw.2021.100067 · Cited by 42
Present scenarios and future prospects of herbal nanomedicine for antifungal therapy
Yadav, R., Pradhan, M., Yadav, K., Mahalvar, A., & Yadav, H. (2022) · Journal of Drug Delivery Science and Technology · doi:10.1016/j.jddst.2022.103430 · Cited by 45
“The majority of them are invasive fungi that necessitate specific treatment and hospitalization [3,4].”
Update on fungal lipid biosynthesis inhibitors as antifungal agents
Vishwakarma, M., Haider, T., & Soni, V. (2023) · Microbiological Research · doi:10.1016/j.micres.2023.127517 · Cited by 51
Zhao, Y., Lee, M. H., Paderu, P., Lee, A., Jimenez-Ortigosa, C., Park, S., Mansbach, R. S., Shaw, K. J., & Perlin, D. S. (2018) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00425-18 · Cited by 42
“Despite advances in antifungal therapy, invasive fungal infections remain major causes of morbidity and death among immunocompromised patients (20).”
BackgroundIntegrity under stress: Host membrane remodelling and damage by fungal pathogens
Westman, J., Hube, B., & Fairn, G. D. (2019) · Cellular Microbiology · doi:10.1111/cmi.13016 · Cited by 42
“Indeed, mortality rates associated with fungal diseases are similar to tuberculosis and higher than malaria (Bongomin et al., 2017; Brown et al., 2012).”
BackgroundContrasts between mucormycosis and aspergillosis in oncohematological patients
Климко, Н. Н., Khostelidi, S. N., Витальевна, Ш. О., Волкова, А. Г., Popova, M. O., Uspenskaya, O. S., Владимировна, Ш. Т., Богомолова, Т. С., Ignatyeva, S. M., Zubarovskaya, L. S., et al. (2018) · Medical Mycology · doi:10.1093/mmy/myy116 · Cited by 50
Rivero-Menéndez, O., Cuenca‐Estrella, M., & Alastruey‐Izquierdo, A. (2020) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkaa351 · Cited by 43
Rational Design of an Antifungal Polyacrylamide Library with Reduced Host-Cell Toxicity
Schaefer, S., Phuong, P. T. T., Brunke, S., Hube, B., Jung, K., Lenardon, M. D., & Boyer, C. A. (2021) · ACS Applied Materials & Interfaces · doi:10.1021/acsami.1c05020 · Cited by 42
Sama‐ae, I., Pattaranggoon, N. C., & Tedasen, A. (2023) · Journal of Molecular Graphics and Modelling · doi:10.1016/j.jmgm.2023.108435 · Cited by 49
Yao, L., Zhang, Y., Li, W., Chung, C., Guan, J., Zhang, W., Chiang, Y., & Lee, T.-Y. (2023) · Protein Science · doi:10.1002/pro.4758 · Cited by 46
“Fungal infections are an increasingly concerning issue world-wide, with an estimated 1 billion individuals affected by fungal diseases (Bongomin et al., 2017; Cornely et al., 2017).”
Diagnostic Performance of a Novel Multiplex PCR Assay for Candidemia among ICU Patients
Fuchs, S., Lass‐Flörl, C., & Posch, W. (2019) · Journal of Fungi · doi:10.3390/jof5030086 · Cited by 45
Metabolic Reprogramming in the Opportunistic Yeast Candida albicans in Response to Hypoxia
Burgain, A., Tebbji, F., Khemiri, I., & Sellam, A. (2020) · mSphere · doi:10.1128/msphere.00913-19 · Cited by 49
“Candida albicans represents a major component of the human disease burden caused by fungi, and it is the most common cause of deadly invasive candidiasis (1).”
BackgroundNovel Antifungal Agents and Their Activity against Aspergillus Species
Vahedi‐Shahandashti, R., & Lass‐Flörl, C. (2020) · Journal of Fungi · doi:10.3390/jof6040213 · Cited by 51
“Invasive fungal infections (IFI) are responsible for over one million deaths annually, which is a significant global health problem [1,2].”
BackgroundEstimation of the burden of tinea capitis among children in Africa
Bongomin, F., Olum, R., Nsenga, L., Namusobya, M. S., Russell, L., de Sousa, E., Osaigbovo, I. I., Kwizera, R., & Baluku, J. B. (2020) · Mycoses · doi:10.1111/myc.13221 · Cited by 49
Self-citationThe Aspergillus Lateral Flow Assay for the Diagnosis of Invasive Aspergillosis: an Update
Jenks, J. D., Miceli, M. H., Prattes, J., Mercier, T., & Hoenigl, M. (2020) · Current Fungal Infection Reports · doi:10.1007/s12281-020-00409-z · Cited by 52
Enhanced Efflux Pump Expression in Candida Mutants Results in Decreased Manogepix Susceptibility
Liston, S. D., Whitesell, L., Kapoor, M., Shaw, K. J., & Cowen, L. E. (2020) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00261-20 · Cited by 39
Pathways of heme utilization in fungi
Kornitzer, D., & Roy, U. (2020) · Biochimica et Biophysica Acta (BBA) - Molecular Cell Research · doi:10.1016/j.bbamcr.2020.118817 · Cited by 40
Nanopore Sequencing of the Fungal Intergenic Spacer Sequence as a Potential Rapid Diagnostic Assay
Morrison, G. A., Fu, J., Lee, G. C., Wiederhold, N. P., Cañete-Gibas, C. F., Bunnik, E. M., & Wickes, B. L. (2020) · Journal of Clinical Microbiology · doi:10.1128/jcm.01972-20 · Cited by 42
Beat the heat: correlates, compounds, and mechanisms involved in fungal thermotolerance
Mattoon, E. R., Casadevall, A., & Cordero, R. J. B. (2021) · Fungal Biology Reviews · doi:10.1016/j.fbr.2021.03.002 · Cited by 45
Duong, T.-M. N., Le, T., Tran, K. H., Nguyen, P. T., Nguyen, B. T., Nguyen, T., Nguyen, H. P., Nguyen, B. T., Fisher, M. C., Rhodes, J. L., et al. (2021) · Environmental Microbiology · doi:10.1111/1462-2920.15660 · Cited by 43
Update on invasive fungal infections in the Middle Eastern and North African region
Osman, M., Al Bikai, A., Rafei, R., Mallat, H., Dabboussi, F., & Hamze, M. (2020) · Brazilian Journal of Microbiology · doi:10.1007/s42770-020-00325-x · Cited by 39
“It is estimated that ~ 250,000 cases occur annually [10].”
BackgroundInfluentialRayens, E. A., Rabacal, W., Willems, H. M. E., Kirton, G. M., Barber, J. P., Mousa, J. J., Celia-Sanchez, B. N., Momany, M., & Norris, K. A. (2022) · PNAS Nexus · doi:10.1093/pnasnexus/pgac248 · Cited by 40
“6 million fungal disease deaths reported globally (1).”
Invasive pulmonary aspergillosis in the intensive care unit: current challenges and best practices
Gaffney, S. M., Kelly, D., Rameli, P. M., Kelleher, E. M., & Martín‐Loeches, I. (2023) · Apmis · doi:10.1111/apm.13316 · Cited by 51
“Mortality rates have been reported to exceed 90% of cases (7).”
BackgroundCurrent and Potential Applications of Monoterpenes and Their Derivatives in Oral Health Care
Potocka, W., Assy, Z., Bikker, F. J., & Laine, M. L. (2023) · Molecules · doi:10.3390/molecules28207178 · Cited by 46
“The prevalence of invasive fungal infections is estimated to be 1 billion annually, resulting in 1.5 million deaths worldwide [102,103].”
BackgroundInfluentialEmergence of zoonotic sporotrichosis in Brazil: a genomic epidemiology study
dos Santos, A. R., Misas, E., Min, B., Le, N., Bagal, U. R., Parnell, L. A., Sexton, D. J., Lockhart, S. R., Melhem, M. D. S. C., Takahashi, J. P. F., et al. (2024) · The Lancet Microbe · doi:10.1016/s2666-5247(23)00364-6 · Cited by 54
Molecular Diagnostics for Invasive Fungal Diseases: Current and Future Approaches
Pham, D., Sivalingam, V., Tang, H. M., Montgomery, J. M., Chen, S. C. ‐., & Halliday, C. L. (2024) · Journal of Fungi · doi:10.3390/jof10070447 · Cited by 60
“Invasive fungal diseases (IFDs) represent a significant, growing global health threat [1] with expansion of the at-risk population [2].”
BackgroundBongomin, F., Govender, N. P., Chakrabarti, A., Robert-Gangneux, F., Boulware, D. R., Zafar, A., Oladele, R. O., Richardson, M. D., Gangneux, J., Alastruey‐Izquierdo, A., et al. (2019) · European Journal of Clinical Microbiology & Infectious Diseases · doi:10.1007/s10096-019-03600-4 · Cited by 40
Self-citationSpore Germination as a Target for Antifungal Therapeutics
Ortiz, S. C., Huang, M., & Hull, C. M. (2019) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00994-19 · Cited by 41
Mercier, T., Guldentops, E., Lagrou, K., & Maertens, J. A. (2020) · Clinical Infectious Diseases · doi:10.1093/cid/ciaa295 · Cited by 41
Deep fungal infections diagnosed by histology in Uganda: a 70-year retrospective study
Kwizera, R., Bongomin, F., & Lukande, R. L. (2020) · Medical Mycology · doi:10.1093/mmy/myaa018 · Cited by 39
Self-citationJohns, L. E., Goldman, G. H., Ries, L. N. A., & Brown, N. A. (2021) · Fungal Biology Reviews · doi:10.1016/j.fbr.2021.01.002 · Cited by 44
Repurposing and optimization of drugs for discovery of novel antifungals
Donlin, M. J., & Meyers, M. J. (2022) · Drug Discovery Today · doi:10.1016/j.drudis.2022.04.021 · Cited by 41
Molecular Dynamics Investigations of Binding Mechanism for Triazoles Inhibitors to CYP51
Shi, N., Zheng, Q., & Zhang, H. (2020) · Frontiers in Molecular Biosciences · doi:10.3389/fmolb.2020.586540 · Cited by 47
Simm, C., Weerasinghe, H., Thomas, D. R., Harrison, P. F., Newton, H. J., Beilharz, T. H., & Traven, A. (2022) · Microbiology Spectrum · doi:10.1128/spectrum.00100-22 · Cited by 38
A Fun-Guide to Innate Immune Responses to Fungal Infections
Burgess, T. B., Condliffe, A. M., & Elks, P. M. (2022) · Journal of Fungi · doi:10.3390/jof8080805 · Cited by 50
“Because the burden of fungal diseases is greatest in tropical countries, fungal infections are frequently underfunded [2].”
BackgroundPoon, Y., & Hui, M. (2023) · Frontiers in Microbiology · doi:10.3389/fmicb.2023.1105949 · Cited by 52
“Candida are one of the most important agents of fungal infection worldwide and the most frequently isolated fungal species in healthcare-associated infections (Bongomin et al., 2017).”
BackgroundRecent developments in membrane targeting antifungal agents to mitigate antifungal resistance
Mehta, D., Saini, V., & Bajaj, A. (2023) · RSC Medicinal Chemistry · doi:10.1039/d3md00151b · Cited by 49
Therapeutic potentials of ononin with mechanistic insights: A comprehensive review
Bhuia, M. S., Aktar, A., Chowdhury, R., Ferdous, J., Rahman, M. A., Hasan, M. S. A., & Islam, M. T. (2023) · Food Bioscience · doi:10.1016/j.fbio.2023.103302 · Cited by 39
Mudenda, S. (2024) · Pharmacology & Pharmacy · doi:10.4236/pp.2024.154007 · Cited by 51
“Antifungal resistance (AFR) has been reported as a global public health problem and has been recognized as a significant global public health problem, posing serious threats to human health, agriculture, and the environment [74] [108].”
BackgroundInsights into the role of sterol metabolism in antifungal drug resistance: a mini-review
Tanwar, S., Kalra, S., & Bari, V. K. (2024) · Frontiers in Microbiology · doi:10.3389/fmicb.2024.1409085 · Cited by 47
Gharanfoli, A., Mahmoudi, E., Torabizadeh, R., Torabizadeh, R., Katiraii, F., & Faraji, S. (2019) · Current Medical Mycology · doi:10.18502/cmm.5.2.1159 · Cited by 49
“Bacteria and fungi are the etiologic agents of UTI [2].”
BackgroundImmunomodulation for the Treatment of Fungal Infections: Opportunities and Challenges
Ademe, M. (2020) · Frontiers in Cellular and Infection Microbiology · doi:10.3389/fcimb.2020.00469 · Cited by 46
“5 million deaths occur due to fungal infections (Bongomin et al., 2017).”
BackgroundDantas, K. C., Mauad, T., de André, C. D. S., Bierrenbach, A. L., & Saldiva, P. H. N. (2021) · Scientific Reports · doi:10.1038/s41598-021-83587-1 · Cited by 51
“4) 15 (36) 5 (71) 31 (12) 40 (31) 76 (37) 340 (31)”
Verma, N., Singh, S., Singh, M., Chauhan, A., Pradhan, P., Jaiswal, N., Chakrabarti, A., & Singh, M. (2021) · Mycoses · doi:10.1111/myc.13387 · Cited by 41
Fluconazole-loaded thermosensitive system: In vitro release, pharmacokinetics and safety study
Mushtaq, A., Baseer, A., Zaidi, S. S., Khan, M. W., Batool, S., Elahi, E., Aman, W., Naeem, M., & Din, F. U. (2021) · Journal of Drug Delivery Science and Technology · doi:10.1016/j.jddst.2021.102972 · Cited by 40
Invasive Aspergillosis in the Intensive Care Unit
Townsend, L., & Martín‐Loeches, I. (2022) · Diagnostics · doi:10.3390/diagnostics12112712 · Cited by 43
“2 million cases of IPA each year, although this is likely an underestimate [3].”
Mah, J., Nicholas, V., Tayyar, R., Moreno, Á., Murugesan, K., Budvytiene, I., & Banaei, N. (2023) · Clinical Infectious Diseases · doi:10.1093/cid/ciad420 · Cited by 41
Winski, C. J., Qian, Y., Mobashery, S., & Santiago-Tirado, F. H. (2022) · mBio · doi:10.1128/mbio.01539-22 · Cited by 37
Immunotherapies against human bacterial and fungal infectious diseases: A review
Qadri, H., Shah, A. H., Alkhanani, M., Almilaibary, A., & Mir, M. A. (2023) · Frontiers in Medicine · doi:10.3389/fmed.2023.1135541 · Cited by 44
“The cytotoxicity of the currently available antifungal drugs is a significant restriction on their usage (123, 127, 128).”
BackgroundRetractedThe emerging role of extracellular vesicles in fungi: a double-edged sword
Lai, Y., Jiang, B., Hou, F., Huang, X.-H., Ling, B., Lü, H., Zhong, T., & Huang, J. (2023) · Frontiers in Microbiology · doi:10.3389/fmicb.2023.1216895 · Cited by 42
Paving the way for affordable and equitable liposomal amphotericin B access worldwide
Lee, J. S. F., Cohen, R. M., Khan, R. A., Burry, J., Casas, E. C., Chung, H. Y., Costa, L. H., Ford, N. P., Galvao, D. L. N., Aguilar, N. G., et al. (2024) · The Lancet Global Health · doi:10.1016/s2214-109x(24)00225-0 · Cited by 50
“34 Although this estimate might be considered optimistic, access to amphotericin B is crucial, including for the top ranked Critical group of fungal pathogens by WHO ( Cryptococcus neoformans , Candida auris , Aspergillus fumigatus , and Candida albicans ) that can mostly be treated with…”
Haranahalli, K., Lazzarini, C., Sun, Y., Zambito, J., Pathiranage, S., McCarthy, J., Mallamo, J. P., Poeta, M. D., & Ojima, I. (2019) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.9b01004 · Cited by 39
Nanosystems against candidiasis: a review of studies performed over the last two decades
Araújo, V. H. S., Duarte, J. L., Carvalho, G. C., Silvestre, A. L. P., Fonseca‐Santos, B., Marena, G. D., Ribeiro, T. D. C., Ramos, M. A. D. S., Bauab, T. M., & Chorilli, M. (2020) · Critical Reviews in Microbiology · doi:10.1080/1040841x.2020.1803208 · Cited by 39
Effects of Propolis on Infectious Diseases of Medical Relevance
Rivera-Yañez, N., Rivera-Yañez, C. R., Pozo‐Molina, G., Méndez-Catalá, C. F., Reyes‐Reali, J., Mendoza‐Ramos, M. I., Méndez‐Cruz, A. R., & Nieto-Yáñez, Ó. (2021) · Biology · doi:10.3390/biology10050428 · Cited by 43
Chen, Y.-C., Yang, Y., Zhang, C., Chen, H., Chen, F., & Wang, K. (2021) · Frontiers in Microbiology · doi:10.3389/fmicb.2021.746006 · Cited by 43
Accelerating the discovery of antifungal peptides using deep temporal convolutional networks
Singh, V., Shrivastava, S., Singh, S. K., Kumar, A., & Saxena, S. (2022) · Briefings in Bioinformatics · doi:10.1093/bib/bbac008 · Cited by 38
Gonçalves, M. F. M., Hilário, S., de Peer, Y. V., Esteves, A. C., & Alves, A. (2021) · Journal of Fungi · doi:10.3390/jof8010031 · Cited by 39
“The number of fungal infections—invasive candidiasis, pneumonia, aspergillosis, cryptococcal meningitis and histoplasmosis—has increased over the last years [71].”
BackgroundSiscar-Lewin, S., Gabaldón, T., Aldejohann, A. M., Kurzai, O., Hube, B., & Brunke, S. (2021) · mBio · doi:10.1128/mbio.01128-21 · Cited by 36
“Candida species are among the most important human fungal pathogens and cause millions of mucosal and life-threatening systemic infections each year (1).”
BackgroundWroński, M., Trawiński, J., & Skibiński, R. (2023) · Journal of Hazardous Materials · doi:10.1016/j.jhazmat.2023.133167 · Cited by 44
Wolfgruber, S., Sedik, S., Klingspor, L., Tortorano, A. M., Gow, N. A. R., Lagrou, K., Gangneux, J., Maertens, J. A., Meis, J. F. G. M., Lass‐Flörl, C., et al. (2024) · Mycopathologia · doi:10.1007/s11046-024-00871-0 · Cited by 44
“Globally, candidemia accounts for approximately 700,000 cases annually [6, 7], with a cumulative incidence of 7.07 episodes per 1000 intensive care unit (ICU) admissions in Europe and a remarkably high 90-day mortality rate of 43% [7–9].”
BackgroundInfluentialBiofilm-Associated Candidiasis: Pathogenesis, Prevalence, Challenges and Therapeutic Options
Amann, V., Kissmann, A., Firacative, C., & Rosenau, F. (2025) · Pharmaceuticals · doi:10.3390/ph18040460 · Cited by 48
Vasileiou, E., Apsemidou, A., Vyzantiadis, T., & Tragiannidis, A. (2018) · Current Medical Mycology · doi:10.18502/cmm.4.3.173 · Cited by 41
Halder, V., Porter, C. B. M., Chavez, A., & Shapiro, R. S. (2019) · Nature Protocols · doi:10.1038/s41596-018-0122-6 · Cited by 37
Schelenz, S., Owens, K., Guy, R. L., Rautemaa‐Richardson, R., Manuel, R. J., Richardson, M. D., Moore, C., Enoch, D., Micallef, C., Howard, P., et al. (2019) · Journal of Infection · doi:10.1016/j.jinf.2019.06.009 · Cited by 38
“Azole resistance in Aspergillus fumigatus: can we retain the clinical use of mold-active antifungal azoles? Clin Infect Dis 2016; 62 (3):362–8.”
BackgroundKwizera, R., Katende, A., Teu, A., Apolot, D., Worodria, W. O., Kirenga, B., & Bongomin, F. (2019) · European Journal of Clinical Microbiology & Infectious Diseases · doi:10.1007/s10096-019-03782-x · Cited by 37
Self-citationDistorted Gold(I)–Phosphine Complexes as Antifungal Agents
Dennis, E. K., Kim, J. H., Parkin, S., Awuah, S. G., & Garneau‐Tsodikova, S. (2019) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.9b01436 · Cited by 39
de Oliveira, H. C., Joffe, L. S., Simon, K. S., Castelli, R. F., Reis, F. C. G., Bryan, A. M., Borges, B. S., Medeiros, L. C. S., Bocca, A. L., Poeta, M. D., et al. (2020) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00286-20 · Cited by 40
“gattii kills almost 47 200,000 humans each year (1).”
BackgroundStojković, D. S., Días, M. I., Drakulić, D., Barros, L., Stevanović, M. J., Ferreira, I. C. F. R., & Sokóvić, M. (2020) · Pharmaceuticals · doi:10.3390/ph13040078 · Cited by 40
“5 million having fatal consequences [1].”
BackgroundFerling, I., Dunn, J. D., Ferling, A., Soldati, T., & Hillmann, F. (2020) · mBio · doi:10.1128/mbio.00862-20 · Cited by 38
Kukurudz, R. J., Chapel, M., Wonitowy, Q., Adamu Bukari, A.-R., Sidney, B., Sierhuis, R., & Gerstein, A. C. (2022) · G3 · doi:10.1093/g3journal/jkac156 · Cited by 35
“Relatively few species account for most human fungal infections, with Candida albicans the primary species responsible for mucosal disease, Aspergillus fumigatus for allergic disease, and Trichophyton spp. for skin infections (Bongomin et al. 2017).”
BackgroundCandida Infections: Clinical Features, Diagnosis and Treatment
Tamo, S. P. B. (2020) · Infectious Diseases and Clinical Microbiology · doi:10.36519/idcm.2020.0006 · Cited by 53
Jung, K., Chung, M., Bai, H., Chung, B.-Y., & Lee, S. (2021) · Molecules · doi:10.3390/molecules26113476 · Cited by 45
“Recently, it has been estimated that there are more than 4,000,000 infections caused by opportunistic fungal pathogens annually [1].”
BackgroundPeng, Y., Lu, Y., Sun, H., Ma, J., Li, X., Han, X., Fang, Z., Tan, J., Qiu, Y., Qu, T., et al. (2024) · Nature Communications · doi:10.1038/s41467-024-52107-w · Cited by 44
Role of lipid transporters in fungal physiology and pathogenicity
Rizzo, J., Stanchev, L. D., Silva, V. K. A., Nimrichter, L., Pomorski, T. G., & Rodrigues, M. L. (2019) · Computational and Structural Biotechnology Journal · doi:10.1016/j.csbj.2019.09.001 · Cited by 39
Dutta, O., Espinosa, V., Wang, K., Avina, S. L., & Rivera, A. (2020) · Frontiers in Cellular and Infection Microbiology · doi:10.3389/fcimb.2020.00321 · Cited by 37
“Fungal infections affect close to one billion individuals worldwide, with a range of diseases spanning mild or superficial skin infections to invasive or chronic infections that can become life-threatening (Bongomin et al., 2017).”
BackgroundAntifungal drugs: An updated review of central nervous system pharmacokinetics
Wirth, F., & Ishida, K. (2020) · Mycoses · doi:10.1111/myc.13157 · Cited by 39
Oladele, R. O., Otu, A. A., Olubamwo, O., Makanjuola, O. B., Ochang, E. A., Ejembi, J., Irurhe, N., Ajanaku, I., Ekundayo, H. A., Olayinka, A., et al. (2020) · Pan African Medical Journal · doi:10.11604/pamj.2020.36.297.23279 · Cited by 40
“The commonest causative organisms of IFIs include Candida spp, Cryptococcus neoformans, Aspergillus spp, Histoplasma capsulatum and Pneumocystis jirovecii [1, 6, 7].”
BackgroundSelf-citationSeidel, C., Moreno-Velásquez, S. D., Ben-Ghazzi, N., Gago, S., Read, N. D., & Bowyer, P. (2020) · Frontiers in Microbiology · doi:10.3389/fmicb.2020.01955 · Cited by 40
“Despite the development of new antifungal drugs and medical procedures, mortality rates for these diseases remain extremely high (Bongomin et al., 2017).”
BackgroundSelf-citationFanou, B. A., Klotoé, J. R., Fah, L., Dougnon, V. T., Koudokpon, H., Toko, G., & Loko, F. (2020) · BMC Complementary Medicine and Therapies · doi:10.1186/s12906-020-03080-6 · Cited by 40
Protein Acetylation/Deacetylation: A Potential Strategy for Fungal Infection Control
Chen, J.-Z., Liu, Q., Zeng, L., & Huang, X. (2020) · Frontiers in Microbiology · doi:10.3389/fmicb.2020.574736 · Cited by 38
Comprehensive genetic analysis of adhesin proteins and their role in virulence ofCandida albicans
Rosiana, S., Zhang, L., Kim, G. H., Revtovich, A. V., Uthayakumar, D., Sukumaran, A., Geddes‐McAlister, J., Kirienko, N. V., & Shapiro, R. S. (2021) · Genetics · doi:10.1093/genetics/iyab003 · Cited by 43
T cell responses to control fungal infection in an immunological memory lens
Sharma, J., Mudalagiriyappa, S., & Nanjappa, S. G. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.905867 · Cited by 42
“Masking of beta(1-3)-glucan in the cell wall of candida albicans from detection by innate immune cells depends on phosphatidylserine.”
Background
Metadata
- Authors
- Bongomin, F., Gago, S., Oladele, R., & Denning, D.
- Affiliations
- University of Manchester (GB)
- Corresponding author
- Denning, David
- Venue
- Journal of Fungi
- Publisher
- MDPI AG
- Published
- 2017-10-18
- Volume
- 3
- Issue
- 4
- Pages
- 57
- ISSN
- 2309-608X (ISSN-L)
- PMC
- PMC5753159
- OpenAlex
- W2767031614
- Semantic Scholar
- a31bc4c8c2356520b0818d41b5c4a2e2091b6f32
- Cited by
- 2,953
- References
- 192
- Citations by year
- 2026: 280 · 2025: 388 · 2024: 518 · 2023: 436 · 2022: 427 · 2021: 370 · 2020: 307 · 2019: 156 · 2018: 67 · 2017: 2
- FWCI
- 22.27
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- Journal of Fungi (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Research Explorer (The University of Manchester) (publishedVersion, cc-by)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Funders
- National Centre for the Replacement, Refinement and Reduction of Animals in Research (NC/P002390/1)
- Topics
- Health Sciences › Medicine › Infectious Diseases › Antifungal resistance and susceptibility
- Health Sciences › Medicine › Infectious Diseases › Fungal Infections and Studies
- Health Sciences › Medicine › Dermatology › Nail Diseases and Treatments
- Keywords
- fungal infection, disease burden estimation, prevalence, chronic pulmonary aspergillosis, cryptococcal meningitis, invasive candidiasis, Pneumocystis carinii pneumonia, invasive aspergillosis, disseminated histoplasmosis, fungal asthma, fungal keratitis, HIV/AIDS, antifungal therapy, estimation accuracy
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-10-10, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-10 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.